(A Peer Review Journal)
e–ISSN: 2408–5162; p–ISSN: 2048–5170


Pages: 158-164
D.I. Ugwuja, U.C. Okoro

keywords: Drugs, discovery, computer, pharmacology, pharmacophore, ligand, structure


Driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor. Computer based drug design is an alternative to the conventional process of drug development. It involves modifying a known drug for new therapeutic indication using computer technology. It has the advantage of being cost effective and time saving. The success in this area are due to identifications of molecular targets, elucidation of 3D structures by X-ray crystallography, NMR, Data availability (for biological targets and ligand) and availability of computer aided software’s. Computational drug design can be divided into two, which are structure-based and ligand based. Ligand based makes use of the knowledge of known active and inactive molecules for chemical similarity search or Quantitative Structure-Activity Relation (QSAR). The structured based make use of the knowledge of the target protein structure and is used when the data-base of the crystalline target proteins are available. The ligand based on the other hand is used when the 3D structures of the target proteins are not available.


Afshar M, Prescott C & Varani G 1999. Structure based and combinational search for new RNA-binding drugs. Curr.Opin. Biotech., 10: 59-63. Bailey-Kellogg C, Widge A, Kelley J, Berardi M, Bushweller J & Donald B 2000. The NOESY jigsaw: Automated protein, structure and main-chain assignment from sparse, unassigned NMR data. J. Comput. Biol. 7: 537–558; 44: 1349–1355. Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A, Mohanty P, Fichman M, Sharadendu A, Nudelman R, Kauffman M, Noiman S 2006. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression". J. Medicinal Chem., 49(11): 3116–35. Beddell CR, Goodford PJ, Norrington FE 1976. compounds designed to fit a site of structure in human haemoglobin. Br. J. Pharmacol, 57: 201 – 209. Blandell TL 1996. Structure – based drug design. Natune, 38(4) 23 – 26. Congrene M, Muray CW & Blandell TL 2005. Structural biology and drug discovery. Drug Discotoday, 10: 895 – 907. Dodson GG & Mcrcola D 1972. The Structure, chemistry and biological activity of injuli. Adoproteinche, 26: 279 – 402. Dorsey BD, Levin RB, McDaniel SL, Vacca JP, Guare JP, Darke PL, Zugay JA, Emini EA, Schleif WA & Quintero JC 1994. L-735,524: The design of a potent and orally protein structures. Available HIV protease inhibitor. J. Med. Chem., 37: 3443–3451. Drews J 1999. In Quest of Tomorrow’s Medicines. Springer – Verlag, New York, pp. 51 – 68. Ehrlich P, Gesammelte AF & Himmelweit E 1957. Chemoreptors Springer – Verlag, Berlin, 6: 87. Ekins, S., M. J. de Groot, et al. (2001). "Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites." Drug metabolism and disposition 29(7): 936-944 Fleming A 1940. Medicinal important of penecillium. Br. J. Exp. Pathol., 10: 226. Gallego J & Varani G 2001. Targeting RNA with small molecules drugs: Therapeutic promise and chemical challenges. Acc. Chem. Res., 34: 836-843. Grower S, Apushka MA, Fishman GA 2006. Topialdorzolamiide for the treatment of crystoid macular edemoma in patients with refinitis pig metosa. AM J Ophthalmol, 141: 850 – 858. Guner OF & Bowen JP 2014. Setting the record straight: The origin of the pharmacophore concept. J. Chem. Infor. & Modelling, 54(5): 1269-1283. Hopkins A & Groom C 2002. The druggable genome. Nat. Rev. Drug Disco., 1: 727-730. Kapetanovic I 2008. Computer-aided drug discovery and development (CADDD): In silico-chemico-biological approach. Chemico-Biological Interactions, 171(2): 165-176. Kurogi Y & Guner OF 2001. Pharmacophore modelling and three-dimensional database searching for drug design using catalyst." Current Medicinal Chem., 8(9): 1035-1055. Leach AR & Harren J 2007. Structure-based Drug Discovery. Berlin: Springer. ISBN 1-4020-4406-2 Lewis RA 2011. The Development of Molecular Modelling Programs: The Use and Limitations of Physical Models. In Gramatica P, Livingstone DJ, Davis AM. Drug Design Strategies: Quantitative Approaches. Royal Soc. Chem., 88–107. Mahajan AN 2006. A review on molecular docking. Science 40: 123-135. Marshall GR 1987. Computer-aided drug design. Annual Rev. Pharmaco. & Toxicol., 27(1): 193-213. Mauser H & Guba W 2008. Recent developments in de novo design and scaffold hopping. Current Opinion in Drug Discovery & Dev., 11(3): 365–74. More FJ 1989. A History of chemistry McGraw-Hill, New York , pp. 212 – 220 Mountain V 2003. Astex, structural genomix, and syrrx. Chem. Biol., 10: 95–98. 29. Oezguen N, Adamian L, Xu Y, Rajarathnam K & Braun W 2002. Automated assignment and 3D structure calculations using combinations of 2D homonuclear and 3D heteronuclear NOESY spectra. J. Biomol. NMR, 22: 249–263. OvonItzetsin M Wuwy–Kok GB 1993. Rational design of potasiadidase – based inhibits of influaza virus replizatan. Nature, 363: 418 – 423. Pervushin K, Riek R, Wider G & Wutrich K 1997. Attenu-ated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anistropy indicates an avenue to NMR molecule inhibitors of Bcl-2 through structure-based computer structures of very large biological macromolecules in solution. Proc. Natl. Acad. Sci. USA, 94: 12366–12371. Roberts AM 1989. Serendipity. Wily, New York, pp. 66 – 74. Roberts N, Martin J, Kinchington D & Broadhurst A 1990. Rational design of peptide-based HIV proteinase inhibitors. Science, 248: 358–361. Schwartz WB & Eckhardt SB 1990. Drug Discovery: A case book and analysis. Engl. J. Med. 240 p 173. Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, Corbley MJ, Cheung HK, Arduini RM, Mead JN, Newman MN, Papadatos JL, Bowes S, Josiah S & Ling LE 2003. "Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI)". Bioorganic & Medicinal Chem. Letters, 13(24): 4355–4359. Sneader, W. (1985) Drug Discovery. Wiley, New York. Song A 2009. Recent advances in computer aided drug design. Briefings in Bioinformatics, 10(5): 579 – 591. Tegar M & Purnomo H 2013. Tea leaves extracted as anti-malaria based on molecular docking plants. Procedia. Envirtal. Sci., 17: 188-194. Tersett N.K, Bell A.S, Brown D. (1996). Sildenafil (Viagra Tm); A potent and selective inhibitor of type S. CGMP phosphodisterase with utility for the treatment of male erectile dysfunction. Bioorgmed Chem., 6: 1819 –1824. Tures ND, Plattner J, Rittenhouse J, Turon M & Wideburg N 1990. Design, activity and 2.8 A°crystal structure of comparison of homology model to the experimental structure a C2 symmetric inhibitor complexed to HIV-1 protease. Science, 249: 527–533. Verlinde C & Hol W 1994. Structure-based drug design: progress, results and challenges. Structure, 2: 577–587. Zheng D, Huang Y, Moseley H, Xiao R & Aramini J 2003. Assessment of NMR structures: A statistical survey and automated protein fold determination using a minimal NMR constraint strategy. Protein Sci., 30(12): 1232–1246